3 results
The main objective of the study is to determine the albuminuria lowering effect of the GLP1-RA exenetide, SGLT-2 inhibitor dapagliflozin and their combination in patients with type 2 diabetes and micro- or macroalbuminuria.Secondary objectives are…
Primary:To investigate change in 24-hr sodium excretion during dapagliflozintreatment between Baseline (average of Days *3 to *1) and averageof Days 2 to 4 within each study group in patients withtype 2 diabetes mellitus (T2DM) with preserved or…
Primary: * To assess the change baseline in 24-hr proteinuria with dapagliflozin for six weeks relative to placebo treatment in patients with non-diabetic kidney disease and proteinuria > 500 mg/day on stable ACEi or ARB treatment. Secondary…